4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

✍ Scribed by S. Bracarda; P. Koralewski; A. Pluzanska; A. Ravaud; C. Szczylik; C. Chevreau; M. Filipek; B. Melichar; N. Moore; B. Escudier

• Book ID: 118625918
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 85 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)71076-5